Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Asset Writedowns and Impairment (2020 - 2024)

Insight Molecular Diagnostics' Asset Writedowns and Impairment history spans 3 years, with the latest figure at $1.8 million for Q4 2024.

  • For Q4 2024, Asset Writedowns and Impairment rose 45100.0% year-over-year to $1.8 million; the TTM value through Dec 2024 reached $3.6 million, down 47.36%, while the annual FY2024 figure was $6.8 million, 0.64% up from the prior year.
  • Asset Writedowns and Impairment for Q4 2024 was $1.8 million at Insight Molecular Diagnostics, up from -$4000.0 in the prior quarter.
  • Across five years, Asset Writedowns and Impairment topped out at $5.0 million in Q1 2023 and bottomed at -$334000.0 in Q3 2020.
  • The 3-year median for Asset Writedowns and Impairment is $334000.0 (2020), against an average of $1.2 million.
  • The largest YoY upside for Asset Writedowns and Impairment was 45100.0% in 2024 against a maximum downside of 45100.0% in 2024.
  • A 3-year view of Asset Writedowns and Impairment shows it stood at $334000.0 in 2020, then tumbled by 101.2% to -$4000.0 in 2023, then surged by 45100.0% to $1.8 million in 2024.
  • Per Business Quant, the three most recent readings for IMDX's Asset Writedowns and Impairment are $1.8 million (Q4 2024), -$4000.0 (Q4 2023), and $1.8 million (Q3 2023).